Article info

Original research
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

Authors

  1. Correspondence to Dr Ilana Mandel; ilana{at}biondbio.com; Dr Sharad Sharma, Oncology Research, Sanofi, Cambridge, MA, USA; sharad.sharma{at}sanofi.com
View Full Text

Citation

Mandel I, Haves Ziv D, Goldshtein I, et al
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

Publication history

  • Accepted July 17, 2022
  • First published September 12, 2022.
Online issue publication 
September 12, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.